SLC5A2 and chronic kidney disease: Current guidelines including the 2022 Kidney Disease Improving Global Outcomes (KDIGO) guideline recommend the use of GLP‐1RA for those who have not achieved individualized glycemic targets, despite the use of metformin and SGLT2 inhibitor treatment, in people with T2DM and CKD.45